Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $14.1250 (0.28%) ($14.0500 - $14.5450) on Wed. Sep. 30, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.63% (three month average) | RSI | 59 | Latest Price | $14.1250(0.28%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 1.2% a day on average for past five trading days. | Weekly Trend | FOLD advances 1.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(50%) XBI(49%) IWM(47%) IWC(45%) | Factors Impacting FOLD price | FOLD will decline at least -1.315% in a week (0% probabilities). VIXM(-29%) VXX(-14%) UUP(-11%) UNG(-5%) IGOV(-4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.315% (StdDev 2.63%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $13.95(1.25%) | 10 Day Moving Average | $13.88(1.77%) | 20 Day Moving Average | $13.78(2.5%) | To recent high | -11.1% | To recent low | 9.7% | Market Cap | $3.647b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |